Literature DB >> 23897440

Rheumatoid arthritis. Triple therapy or etanercept after methotrexate failure in RA?

Ronald F van Vollenhoven1, Katerina Chatzidionysiou.   

Abstract

Since the 1990s, patients with rheumatoid arthritis have been treated with at least one DMARD. Methotrexate, which is usually the first-line treatment, elicits good or even excellent clinical results in 20–30% of patients—but in most patients it does not. Thus, an important question is what to do after methotrexate failure.

Entities:  

Mesh：

Substances：

Year:  2013        PMID： 23897440     DOI： 10.1038/nrrheum.2013.118

Source DB:  PubMed          Journal:  Nat Rev Rheumatol        ISSN： 1759-4790            Impact factor:   20.543


  10 in total

1.  Comparison of combination therapy with single-drug therapy in early rheumatoid arthritis: a randomised trial. FIN-RACo trial group.

Authors:  T Möttönen; P Hannonen; M Leirisalo-Repo; M Nissilä; H Kautiainen; M Korpela; L Laasonen; H Julkunen; R Luukkainen; K Vuori; L Paimela; H Blåfield; M Hakala; K Ilva; U Yli-Kerttula; K Puolakka; P Järvinen; M Hakola; H Piirainen; J Ahonen; I Pälvimäki; S Forsberg; K Koota; C Friman
Journal:  Lancet       Date:  1999-05-08       Impact factor: 79.321

2.  Conventional combination treatment versus biological treatment in methotrexate-refractory early rheumatoid arthritis: 2 year follow-up of the randomised, non-blinded, parallel-group Swefot trial.

Authors:  Ronald F van Vollenhoven; Pierre Geborek; Kristina Forslind; Kristina Albertsson; Sofia Ernestam; Ingemar F Petersson; Katerina Chatzidionysiou; Johan Bratt
Journal:  Lancet       Date:  2012-03-29       Impact factor: 79.321

3.  Guidelines for initiation of anti-tumour necrosis factor therapy in rheumatoid arthritis: similarities and differences across Europe.

Authors:  P Emery; R Van Vollenhoven; M Ostergaard; E Choy; B Combe; W Graninger; K Krueger; M Matucci-Cerinic; F Navarro; P van Riel; L Settas; S Steinfeld
Journal:  Ann Rheum Dis       Date:  2009-04       Impact factor: 19.103

4.  Comparison of treatment strategies in early rheumatoid arthritis: a randomized trial.

Authors:  Yvonne P M Goekoop-Ruiterman; Jeska K de Vries-Bouwstra; Cornelia F Allaart; Derkjen van Zeben; Pit J S M Kerstens; J Mieke W Hazes; Aelko H Zwinderman; André J Peeters; Johanna M de Jonge-Bok; Constant Mallée; Wim M de Beus; Peter B J de Sonnaville; Jacques A P M Ewals; Ferdinand C Breedveld; Ben A C Dijkmans
Journal:  Ann Intern Med       Date:  2007-03-20       Impact factor: 25.391

5.  A randomized comparative effectiveness study of oral triple therapy versus etanercept plus methotrexate in early aggressive rheumatoid arthritis: the treatment of Early Aggressive Rheumatoid Arthritis Trial.

Authors:  Larry W Moreland; James R O'Dell; Harold E Paulus; Jeffrey R Curtis; Joan M Bathon; E William St Clair; S Louis Bridges; Jie Zhang; Theresa McVie; George Howard; Désirée van der Heijde; Stacey S Cofield
Journal:  Arthritis Rheum       Date:  2012-09

6.  Addition of infliximab compared with addition of sulfasalazine and hydroxychloroquine to methotrexate in patients with early rheumatoid arthritis (Swefot trial): 1-year results of a randomised trial.

Authors:  R F van Vollenhoven; S Ernestam; P Geborek; I F Petersson; L Cöster; E Waltbrand; A Zickert; J Theander; A Thörner; H Hellström; A Teleman; C Dackhammar; F Akre; K Forslind; L Ljung; R Oding; A Chatzidionysiou; M Wörnert; J Bratt
Journal:  Lancet       Date:  2009-08-08       Impact factor: 79.321

Review 7.  EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs.

Authors:  Josef S Smolen; Robert Landewé; Ferdinand C Breedveld; Maxime Dougados; Paul Emery; Cecile Gaujoux-Viala; Simone Gorter; Rachel Knevel; Jackie Nam; Monika Schoels; Daniel Aletaha; Maya Buch; Laure Gossec; Tom Huizinga; Johannes W J W Bijlsma; Gerd Burmester; Bernard Combe; Maurizio Cutolo; Cem Gabay; Juan Gomez-Reino; Marios Kouloumas; Tore K Kvien; Emilio Martin-Mola; Iain McInnes; Karel Pavelka; Piet van Riel; Marieke Scholte; David L Scott; Tuulikki Sokka; Guido Valesini; Ronald van Vollenhoven; Kevin L Winthrop; John Wong; Angela Zink; Désirée van der Heijde
Journal:  Ann Rheum Dis       Date:  2010-05-05       Impact factor: 19.103

8.  Treatment of rheumatoid arthritis with methotrexate and hydroxychloroquine, methotrexate and sulfasalazine, or a combination of the three medications: results of a two-year, randomized, double-blind, placebo-controlled trial.

Authors:  James R O'Dell; Robert Leff; Gail Paulsen; Claire Haire; Jack Mallek; P James Eckhoff; Ana Fernandez; Kent Blakely; Steven Wees; Julie Stoner; Stephen Hadley; Jeffrey Felt; William Palmer; Paul Waytz; Melvin Churchill; Lynell Klassen; Gerald Moore
Journal:  Arthritis Rheum       Date:  2002-05

9.  Treatment of rheumatoid arthritis with methotrexate alone, sulfasalazine and hydroxychloroquine, or a combination of all three medications.

Authors:  J R O'Dell; C E Haire; N Erikson; W Drymalski; W Palmer; P J Eckhoff; V Garwood; P Maloley; L W Klassen; S Wees; H Klein; G F Moore
Journal:  N Engl J Med       Date:  1996-05-16       Impact factor: 91.245

10.  Therapies for active rheumatoid arthritis after methotrexate failure.

Authors:  James R O'Dell; Ted R Mikuls; Thomas H Taylor; Vandana Ahluwalia; Mary Brophy; Stuart R Warren; Robert A Lew; Amy C Cannella; Gary Kunkel; Ciaran S Phibbs; Aslam H Anis; Sarah Leatherman; Edward Keystone
Journal:  N Engl J Med       Date:  2013-06-11       Impact factor: 91.245
  10 in total
  2 in total

Review 1.  Is non-biological treatment of rheumatoid arthritis as good as biologics?

Authors:  Jyoti Ranjan Parida; Durga Prasanna Misra; Anupam Wakhlu; Vikas Agarwal
Journal:  World J Orthop       Date:  2015-03-18

2.  Bruton's tyrosine kinase inhibitor BMS-986142 in experimental models of rheumatoid arthritis enhances efficacy of agents representing clinical standard-of-care.

Authors:  Kathleen M Gillooly; Claudine Pulicicchio; Mark A Pattoli; Lihong Cheng; Stacey Skala; Elizabeth M Heimrich; Kim W McIntyre; Tracy L Taylor; Daniel W Kukral; Shailesh Dudhgaonkar; Jignesh Nagar; Dana Banas; Scott H Watterson; Joseph A Tino; Aberra Fura; James R Burke
Journal:  PLoS One       Date:  2017-07-24       Impact factor: 3.240
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.